Impax Asset Management Group plc Buys 4,484 Shares of Edwards Lifesciences Co. (NYSE:EW)

Impax Asset Management Group plc boosted its holdings in Edwards Lifesciences Co. (NYSE:EW) by 34.6% in the fourth quarter, Holdings Channel reports. The firm owned 17,448 shares of the medical research company’s stock after purchasing an additional 4,484 shares during the quarter. Impax Asset Management Group plc’s holdings in Edwards Lifesciences were worth $1,292,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. W.G. Shaheen & Associates DBA Whitney & Co increased its stake in Edwards Lifesciences by 45.9% in the 4th quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 161,221 shares of the medical research company’s stock valued at $11,935,000 after buying an additional 50,744 shares during the last quarter. Rothschild Investment LLC increased its stake in Edwards Lifesciences by 2.1% in the 4th quarter. Rothschild Investment LLC now owns 12,981 shares of the medical research company’s stock valued at $961,000 after buying an additional 263 shares during the last quarter. HealthInvest Partners AB increased its stake in Edwards Lifesciences by 87.1% in the 4th quarter. HealthInvest Partners AB now owns 68,296 shares of the medical research company’s stock valued at $5,070,000 after buying an additional 31,791 shares during the last quarter. Y Intercept Hong Kong Ltd increased its stake in Edwards Lifesciences by 176.5% in the 4th quarter. Y Intercept Hong Kong Ltd now owns 38,221 shares of the medical research company’s stock valued at $2,830,000 after buying an additional 24,398 shares during the last quarter. Finally, Union Bancaire Privee UBP SA acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $1,120,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In other news, Director Steven R. Loranger sold 5,739 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the sale, the director now owns 60,372 shares of the company’s stock, valued at approximately $4,613,628.24. This represents a 8.68 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the sale, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. This trade represents a 26.91 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,489 shares of company stock valued at $2,002,829 in the last quarter. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE EW opened at $71.46 on Wednesday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $42.15 billion, a P/E ratio of 10.25, a P/E/G ratio of 4.82 and a beta of 1.11. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The firm has a 50-day moving average price of $72.78 and a two-hundred day moving average price of $70.18.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on EW shares. Piper Sandler lifted their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Citigroup boosted their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Canaccord Genuity Group boosted their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research note on Thursday, February 13th. Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Finally, Evercore ISI lowered their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research note on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences has a consensus rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.